SCID, or severe combined immunodeficiency, is a group of rare genetic disorders in which a baby is born with a severely damaged or completely absent immune system. It affects roughly 1 in 58,000 to 65,000 newborns in the United States. Without treatment, babies with SCID cannot fight off even common infections, and the condition is fatal, usually within the first year or two of life. With early detection and treatment, however, survival rates now exceed 90%.
How SCID Affects the Immune System
A healthy immune system relies on two key types of white blood cells working together. T-cells attack infected cells directly and coordinate the broader immune response. B-cells produce antibodies that target specific bacteria and viruses. In a baby with SCID, genetic mutations prevent these cells from developing or functioning properly.
The damage often starts with T-cells. Because B-cells depend on signals from T-cells to produce the right antibodies, a baby whose T-cells don’t work will also have failing B-cell function, even if B-cells are technically present. This is why SCID is called “combined” immunodeficiency: both arms of the adaptive immune system are knocked out. A third type of immune cell, natural killer cells, develops through a separate pathway and may still be present in some forms of SCID, offering a small degree of protection. Whether or not a baby has functioning natural killer cells helps doctors gauge the severity of their condition.
What Causes SCID
SCID is always caused by inherited genetic mutations. More than a dozen different genes can be involved, and the specific gene affected determines the type of SCID a baby has. The most common forms break down roughly as follows:
- X-linked SCID (about 42% of cases): Caused by a mutation on the X chromosome, which is why it almost exclusively affects boys. The mutation disrupts a protein that multiple immune-cell types need for growth signaling. Babies with this form typically have no T-cells and no natural killer cells but do have B-cells that can’t function without T-cell help.
- Autosomal recessive SCID (about 22%): Caused by mutations in various genes inherited from both parents, affecting T-cell receptor development or signaling.
- ADA deficiency (about 15%): A missing enzyme causes toxic byproducts to build up inside immune cells, killing T-cells, B-cells, and natural killer cells alike. This form has a unique treatment option (described below).
- JAK3 deficiency (about 6%): Closely mimics X-linked SCID but is inherited from both parents rather than being X-linked.
Because the most common form is X-linked, SCID is diagnosed more often in boys. But the autosomal recessive forms affect boys and girls equally, so the condition can appear in any baby regardless of sex.
Signs and Symptoms
Babies with SCID typically appear healthy at birth. Maternal antibodies passed during pregnancy provide temporary protection, but that shield fades within the first few months. By 2 to 4 months of age, untreated babies begin developing infections that are unusually frequent, severe, or caused by organisms that rarely make healthy infants sick.
Common early signs include persistent oral thrush that doesn’t respond to standard treatment, chronic diarrhea, and failure to thrive (poor weight gain and slow growth despite adequate feeding). Recurrent ear infections, pneumonia, and skin rashes are also typical. More alarming are opportunistic infections, those caused by germs that a working immune system easily controls. Pneumonia caused by a fungus called Pneumocystis jirovecii is one of the hallmark infections in undiagnosed SCID. Meningitis, bloodstream infections, and severe viral illnesses can follow.
Before newborn screening became widespread, many babies with SCID were not diagnosed until they were already seriously ill, which dramatically worsened their chances of survival.
How Newborn Screening Works
All 50 U.S. states now screen newborns for SCID using the standard heel-prick blood test performed in the first days of life. The test measures tiny DNA circles called TRECs, which are a natural byproduct of T-cell development. Every time the body creates a new T-cell, these circles are produced and can be detected in a dried blood spot. A baby with very low or undetectable TREC levels likely has poor T-cell production, which flags the need for further testing.
This screening has been transformative. Before it was adopted, SCID was estimated to occur in about 1 in 100,000 births. Once population-wide screening began, the true incidence turned out to be nearly double that, around 1 in 58,000 to 65,000 births. Many cases had simply gone undiagnosed. More importantly, screening catches SCID before infections take hold, and early treatment is the single biggest factor in survival.
If the screening result is abnormal, doctors confirm the diagnosis with blood tests that measure the exact number and types of immune cells. In typical SCID, the T-cell count is extremely low. A milder form called “leaky” or atypical SCID exists where some T-cells are present but still far below normal levels for a baby’s age. Genetic testing then identifies the specific mutation responsible.
Why Early Treatment Matters So Much
The data on timing is striking. Babies who receive a stem cell transplant (also called a bone marrow transplant) before 3.5 months of age and before contracting a serious infection have a five-year survival rate of 80 to 95%, regardless of the type of donor. After 3.5 months, survival drops, partly because older babies have had more time to pick up infections, and partly because age itself appears to matter independently. Even among babies who already have an active infection, those transplanted before 3.5 months do significantly better than those transplanted later.
Newborn screening data from California covering more than 3.2 million infants showed 96% survival among babies identified and treated through the screening program. Across multiple U.S. states, the overall survival rate for screened and treated infants is around 92%. By contrast, large studies from Europe, where newborn screening has been less universal, report survival closer to 70%.
Treatment Options
Stem Cell Transplant
A stem cell transplant is the primary cure for most forms of SCID. The goal is to replace the baby’s defective immune system with healthy stem cells from a donor. These stem cells migrate to the bone marrow, where they begin producing functional T-cells and, in many cases, functional B-cells as well.
The best outcomes occur when a matched sibling donor is available, but most families don’t have one. In those cases, doctors can use partially matched family donors (often a parent) or matched unrelated donors found through registries. Advances in transplant techniques have significantly improved outcomes even with imperfect donor matches, especially when the transplant happens early.
Enzyme Replacement for ADA Deficiency
Babies with the ADA-deficient form of SCID have an additional treatment option. Because their immune cells are being poisoned by toxic metabolic byproducts that accumulate when the ADA enzyme is missing, replacing that enzyme can stabilize the condition. The replacement is given as an intramuscular injection once or twice per week. It clears the toxic buildup, which allows some immune recovery.
Enzyme replacement is not considered a permanent cure, but it serves as a critical bridge. It stabilizes the baby’s health while doctors arrange a stem cell transplant or evaluate whether gene therapy is appropriate. More than 150 patients worldwide have been treated this way. Some children remain on enzyme replacement for extended periods with reasonable clinical stability, though most eventually move to a more definitive therapy.
Gene Therapy
Gene therapy corrects the underlying genetic defect by inserting a working copy of the faulty gene into the baby’s own stem cells. These corrected cells are then returned to the body, where they can produce normal immune cells. Gene therapy has been used successfully in certain forms of SCID, particularly X-linked SCID and ADA-deficient SCID, and is an active area of clinical use at specialized centers.
Protecting a Baby With SCID Before Treatment
Between diagnosis and definitive treatment, keeping the baby infection-free is the top priority. Even a common cold virus can become life-threatening. Families are typically advised to keep the baby away from crowds, public places, and anyone who is even mildly ill. Strict handwashing is essential for everyone in the household and any visitors. Doctors may recommend protective face masks in certain situations and will often prescribe preventive antibiotics, antifungal, and antiviral medications.
Standard childhood vaccines are not given to babies with SCID. Live vaccines, such as the rotavirus vaccine, can actually cause the disease they’re meant to prevent in a baby with no functioning immune system. Breastfeeding also requires careful discussion with doctors, because certain viruses, particularly cytomegalovirus, can be transmitted through breast milk and pose a serious risk to an immunodeficient infant.
SCID was historically called “bubble baby disease” after David Vetter, a boy with SCID who lived in a sterile plastic enclosure for 12 years in the 1970s and 80s. Modern treatment means this kind of prolonged isolation is no longer necessary. With newborn screening catching cases in the first weeks of life, most babies can move quickly toward transplant or gene therapy and eventually develop a functional immune system.